全文获取类型
收费全文 | 16756篇 |
免费 | 2102篇 |
国内免费 | 616篇 |
专业分类
耳鼻咽喉 | 109篇 |
儿科学 | 449篇 |
妇产科学 | 130篇 |
基础医学 | 1629篇 |
口腔科学 | 398篇 |
临床医学 | 2205篇 |
内科学 | 2806篇 |
皮肤病学 | 190篇 |
神经病学 | 1616篇 |
特种医学 | 274篇 |
外国民族医学 | 2篇 |
外科学 | 1197篇 |
综合类 | 2568篇 |
预防医学 | 1361篇 |
眼科学 | 472篇 |
药学 | 2536篇 |
6篇 | |
中国医学 | 749篇 |
肿瘤学 | 777篇 |
出版年
2024年 | 40篇 |
2023年 | 219篇 |
2022年 | 441篇 |
2021年 | 623篇 |
2020年 | 677篇 |
2019年 | 719篇 |
2018年 | 744篇 |
2017年 | 885篇 |
2016年 | 860篇 |
2015年 | 783篇 |
2014年 | 1209篇 |
2013年 | 1259篇 |
2012年 | 1101篇 |
2011年 | 1233篇 |
2010年 | 972篇 |
2009年 | 787篇 |
2008年 | 806篇 |
2007年 | 796篇 |
2006年 | 689篇 |
2005年 | 589篇 |
2004年 | 518篇 |
2003年 | 528篇 |
2002年 | 424篇 |
2001年 | 404篇 |
2000年 | 315篇 |
1999年 | 271篇 |
1998年 | 207篇 |
1997年 | 162篇 |
1996年 | 117篇 |
1995年 | 118篇 |
1994年 | 108篇 |
1993年 | 72篇 |
1992年 | 75篇 |
1991年 | 80篇 |
1990年 | 59篇 |
1989年 | 74篇 |
1988年 | 49篇 |
1987年 | 50篇 |
1986年 | 36篇 |
1985年 | 84篇 |
1984年 | 54篇 |
1983年 | 44篇 |
1982年 | 54篇 |
1981年 | 45篇 |
1980年 | 38篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1977年 | 14篇 |
1976年 | 8篇 |
1973年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
2.
3.
4.
目的观察急性冠状动脉综合征患者介入治疗后血小板活化指标CD62p、CD63及糖蛋白Ⅱb/Ⅲa受体复合物及内皮功能的改变。方法60例急性冠状动脉综合征患者在冠状动脉介入术前和术后即刻以及次日采用流式细胞仪检测血小板活化指标CD62p、CD63及糖蛋白Ⅱb/Ⅲa受体复合物;双抗体夹心固相酶联免疫吸附试验测定血浆假血友病因子的表达水平;放射免疫测定法测定血浆内皮素1表达水平;酶法测定血浆一氧化氮的含量;彩色多谱勒超声诊断仪测量内皮依赖性血管舒张功能。选择健康体检者和稳定型心绞痛患者各30例作对照,观察急性冠状动脉综合征患者冠状动脉介入前后指标的变化并与对照组比较。结果与健康对照组和稳定型心绞痛组比,急性冠状动脉综合征组CD62p、CD63及糖蛋白Ⅱb/Ⅲa受体复合物明显增高(P<0.05或0.01);急性冠状动脉综合征患者介入术后即刻CD62p、CD63和糖蛋白Ⅱb/Ⅲa受体复合物与术前相比明显增高(P<0.01),但术后24h较术前无明显变化(P>0.05)。与健康对照组和稳定型心绞痛组比,急性冠状动脉综合征组假血友病因子、内皮素1的表达水平明显增高(P<0.01),内皮依赖性血管舒张功能和一氧化氮降低(P<0.05或<0.01);急性冠状动脉综合征患者介入术后即刻血浆假血友病因子和内皮素1水平升高(P<0.05或P<0.01),内皮依赖性血管舒张功能和一氧化氮水平降低(P<0.05),且介入术后24h假血友病因子水平也较术前升高(P<0.05),内皮依赖性血管舒张功能降低(P<0.05),但内皮素1和一氧化氮水平与术前差异无显著性(P>0.05)。结论血小板活化和内皮功能的损伤在急性冠状动脉综合征发生和发展过程中起重要的作用,冠状动脉介入术后血管内皮受到一定损伤,血小板有一定程度的激活。 相似文献
5.
Robert M. Levy Roman Saikovsky Evgeniya Shmidt Alexander Khokhlov Bruce P. Burnett 《Nutrition Research》2009
Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups. 相似文献
6.
Amit Dang MBBS Gaurav Garg Padmanabh V. Rataboli MD 《The International journal of eating disorders》2009,42(4):385-386
Nocturnal Sleep‐Related Eating Disorder (NSRED) is a well‐documented sleeping disorder where the person is reported to experience bizarre eating behavior during sleep. Although various causes are implicated in this disorder, role of drugs cannot be ruled out. Here we narrate an interesting rare case report of a drug‐induced new onset NSRED, where a 45‐year‐old man on zolipdem performed an unexpected and bizarre eating behavior during somnambulistic state, type of which has not been reported earlier in the literature. The case falls under even rarer category as such behavior in sleep is reported mainly in woman. © 2008 by Wiley Periodicals, Inc. Int J Eat Disord 2009 相似文献
7.
血小板活化因子在急性肝肾衰竭动物模型中对肾功能的影响 总被引:1,自引:0,他引:1
目的:了解血小板活化因子(PAF)在急性肝、肾衰竭动物模型中对肾功能的影响及可能的作用机制。方法:设4组大鼠,分别注射D-氨基半乳糖(D-GaLN)加内毒素(LPS),D-GaLN加PAF,D-GaLN加LPS加PAF受体拮抗剂及生理盐水,诱导急性肝、肾衰竭动物模型,测肝、肾功能指标并观察肝、肾组织病理改变。结果:注射D-GaLN大鼠的血清丙氨酸氨基转移酶、总胆红素比生理盐水组升高10倍以上,差异有显著性,病检有肝细胞坏死。注射PAF或LPS组与PAF受体拮抗剂组或生理盐水组比,肾功能指标差异有显著性。肾组织病检可见部分肾小管坏死。结论:PAF与急性肝、肾衰竭动物模型中的急性肾衰有关;PAF可能参与了内毒素相关的肝肾综合征(HRS)的形成;PAF受体拮抗剂对HRS可能有治疗作用。 相似文献
8.
9.
99Tcm标记人源化抗人血小板膜糖蛋白Ⅲ a单克隆抗体SZ21F(ab)2血栓栓塞显像 总被引:1,自引:1,他引:0
目的用动物血栓栓塞模型显像评估99^Tc^m标记人源化抗人血小板膜糖蛋白(GP)Ⅲa单克隆抗体(简称单抗)F(ab)2片段SZ21F(ab)2的应用价值。方法通过体外抑制二磷酸腺苷(ADP)诱导的犬血小板聚集实验,评估SZ21F(ab)2与血小板结合的亲和性和特异性。以2-亚氨基噻吩盐酸盐(IT)法修饰SZ21F(ab)2分子的亚氨基,以99^Tc^m-葡庚糖酸钠(GH)转换络合法进行标记。分别用快速薄层层析(ITLC)法和ELISA测定标记物的放化纯及生物活性。对3条肺动脉血栓和8条(包括上述3条)后肢深静脉血栓栓塞比格犬模型进行显像研究。结果SZ21F(ab)2抑制ADP诱导的犬富含血小板血浆(PRP)聚集实验的半数有效剂量(IC50)为(2.49±1.88)μg/ml。ITLC法测得标记物的放化纯为90%~95%,ELISA测定结果表明标记后抗体保留了免疫活性。注射显像剂后1h,肺动脉血栓部位和后肢深静脉血栓部位均出现放射性浓聚。注射后3h,在体显像肺动脉血栓和后肢深静脉血栓栓塞模型的放射性靶/本底(T/B)比值分别为3.03±1.18和3.51±0.62。肺动脉血栓部位和后肢深静脉血栓部位的每克组织百分注射剂量率(%ID/g)分别为0.083%ID/g和0.076%ID/g。体外检测结果表明:肺动脉血栓与正常肺组织的单位质量放射性比值平均为12.8,后肢深静脉血栓与血液的单位质量放射性比值平均为5.2,与肌肉的比值平均为127.0。结论99^Tc^m-SZ21F(ab)2与人血小板具有较高的亲和力,有潜在的血栓显像应用前景。 相似文献
10.
Sajeel Chowdhary MD Lisa M. Chalmers PA-C Marc Chamberlain MD 《Journal of neuroimaging》2007,17(1):69-73
In the course of 1 year at a tertiary cancer center, 3 patients (2 men; 1 woman; age 51-75 years) were seen in neurological consultation (1.5% of all consultations). Clinical course in all patients was of a progressive neurologic disorder not consistent with either a primary or secondary malignancy. Magnetic resonance (MR) imaging was most informative with respect to diagnosis and subsequent management. Brain biopsy was performed in all patients to assist in both diagnosis and prognostication. All patients were determined to have progressive multifocal leukoencephalopathy (PML) by brain biopsy. 相似文献